Radiaciones electromagnéticas generadas por las nuevas tecnologías de la comunicación que afectan a la salud y al medioambiente.
miércoles, 19 de agosto de 2020
martes, 18 de agosto de 2020
domingo, 16 de agosto de 2020
fármaco para hipertensos que no hagan más probable infección por COVID
We suggest that patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs, are at higher risk for severe COVID-19 infection and, therefore, should be monitored for ACE2-modulating medications, such as ACE inhibitors or ARBs. Based on a PubMed search on Feb 28, 2020, we did not find any evidence to suggest that antihypertensive calcium channel blockers increased ACE2 expression or activity, therefore these could be a suitable alternative treatment in these patients.
POTENTIAL CBD CORONAVIRUS TREATMENT? (¿CBD como potencial tratamiento del coronavirus?)
Enlace al artículo científico:
https://www.preprints.org/manuscript/202004.0315/v1
Cannabis (en concreto se habla del CBD) contra el Alzheimer
The neuroprotective actions of CBD in AD was also studied by Iuvone et al. [30] by evaluating the effect of cannabidiol, a major non-psychoactive component of the marijuana plant (Cannabis sativa) on β-amyloid peptide-induced toxicity in cultured rat pheocromocytoma PC12 cells. β-amyloid peptide induced a strong reduction of cell survival as well as an increased reactive oxygen species (ROS) production, lipid peroxidation, caspase 3 (a key enzyme in the apoptosis cell-signalling cascade) appearance, DNA fragmentation and intracellular calcium was osbserved. Treatment of the cells with cannabidiol, prior to β-amyloid peptide exposure, significantly elevated cell survival while it decreased ROS production, lipid peroxidation, caspase 3 levels, DNA fragmentation and intracellular calcium. These results indicate that cannabidiol exerts a neuroprotective effects against β-amyloid peptide toxicity suggesting the a possible involvement of cannabidiol in the signalling pathway for this neuroprotection. This hypothesis was supported by a further study where CBD inhibited both nitrite production and nitric oxide synthase (iNOS) protein expression induced by beta-A [31]. These results of in vitro studies were confirmed in vivo with a mouse model of AD-related neuroinflammation. Mice were inoculated with human beta-A into the right dorsal hippocampus, and treated daily with vehicle or CBD (2.5 or 10 mg kg, i.p.) for 7 days. In contrast to vehicle, CBD dose-dependent significantly inhibited mRNA for glial fibrillary acidic protein and the protein expression in beta-A injected animals. Moreover, under the same experimental conditions, CBD impaired iNOS and IL-1beta protein expression, and the related NO and IL-1beta release [32]. The possibility of CBD inhibiting beta-A-induced neurodegeneration is very promising to AD prevention
martes, 17 de marzo de 2020
Suscribirse a:
Entradas (Atom)